Mathew A. Vadas
Camperdown, NSW 2050, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis.
Journal: Journal of translational medicine
Published: December 22, 2023
Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate.
Journal: Frontiers in immunology
Published: June 23, 2023
Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.
Journal: Cellular and molecular life sciences : CMLS
Published: March 24, 2022
Identification of circulating sphingosine kinase-related metabolites for prediction of type 2 diabetes.
Journal: Journal of translational medicine
Published: June 17, 2021
The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking.
Journal: Cancers
Published: February 28, 2021
Regulation of hepatic insulin signaling and glucose homeostasis by sphingosine kinase 2.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 12, 2020
The VE-Cadherin/β-catenin signalling axis regulates immune cell infiltration into tumours.
Journal: Cancer letters
Published: July 22, 2020
YAP and the RhoC regulator ARHGAP18, are required to mediate flow-dependent endothelial cell alignment.
Journal: Cell communication and signaling : CCS
Published: May 27, 2019
Last Updated: 09/26/2026